ArticleTargeted oncology2020

Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.

Ramesh K Ramanathan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.